Silence Therapeutics (SLN) Q3 FY2024 earnings: revenue $1 million
Silence Therapeutics plc (SLN) reported revenue of $1 million for Q3 FY2024, the quarter ended 30 September 2024. Net income was -$36 million, and diluted earnings per share $-0.25. The figures are the company's own, from the 10-Q it filed with the SEC on 6 November 2025.
Revenue$1 million
Net income-$36 million
Diluted EPS$-0.25
QuarterQ3 FY2024ended 30 September 2024
The quarter, against the one before and a year earlier
| Line | Q3 FY2024 | Q2 FY2024 | A year earlier | Change on the year |
|---|---|---|---|---|
| Revenue | 1.5 | 0.8 | n/a | n/a |
| Cost of revenue | 3.6 | 3.3 | n/a | n/a |
| Gross profit | -2.1 | -2.6 | n/a | n/a |
| Gross margin | -142.9% | -340.9% | n/a | |
| Research and development | 20.2 | 13.8 | n/a | n/a |
| Operating income | -30.0 | -23.4 | n/a | n/a |
| Operating margin | -2002.5% | -3093.7% | n/a | |
| Pre-tax income | -35.5 | -19.5 | n/a | n/a |
| Income tax | 0.0 | 0.2 | n/a | n/a |
| Net income | -35.5 | -19.8 | n/a | n/a |
| Net margin | -2372.8% | -2613.1% | n/a | |
| Diluted EPS | -$0.25 | -$0.14 | n/a | n/a |
$ million except per share.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow and capital returned
| Line | Q3 FY2024 | Q2 FY2024 | A year earlier | Change on the year |
|---|---|---|---|---|
| Operating cash flow | -25.6 | -5.4 | n/a | n/a |
| Capital expenditure | 0.1 | 0.1 | n/a | n/a |
| Free cash flow | -25.7 | -5.5 | n/a | n/a |
| Free cash flow margin | -1713.7% | -726.7% | n/a | |
| Cash from investing | -38.1 | -0.0 | n/a | n/a |
| Cash from financing | 8.0 | 1.2 | n/a | n/a |
| Depreciation | 0.1 | 0.1 | n/a | n/a |
| Share-based compensation | 4.1 | 4.1 | n/a | n/a |
| Diluted shares, weighted | 141m | 140m | n/a | n/a |
| Shares outstanding at period end | 142m | 142m | n/a | n/a |
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet at quarter end
| Line | Q3 FY2024 | Q2 FY2024 | A year earlier | Change on the year |
|---|---|---|---|---|
| Shareholders' equity | 127 | 143 | n/a | n/a |
| Goodwill | 9.4 | n/a | n/a | n/a |
| Cash and equivalents | 82.9 | 138 | n/a | n/a |
Questions
What was Silence Therapeutics' revenue in Q3 FY2024?
Silence Therapeutics (SLN) reported revenue of $1 million for Q3 FY2024, the quarter ended 30 September 2024.
How much did Silence Therapeutics earn in Q3 FY2024?
Net loss for Q3 FY2024 was $36 million, and the diluted loss per share $0.25.
When did Silence Therapeutics report Q3 FY2024 results?
Silence Therapeutics filed its 10-Q for the quarter ended 30 September 2024 with the SEC on 6 November 2025.
Quarterly results, the last 10 quarters
| Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.7 | 0.8 | 1.5 | 25.3 | 0.1 | 0.2 | 0.2 | 0.0 | 0.4 | 0.0 |
| Cost of revenue | 2.8 | 3.3 | 3.6 | 2.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
| Gross profit | 12.9 | -2.6 | -2.1 | 23.3 | 0.1 | 0.1 | 0.1 | 0.0 | 0.4 | 0.0 |
| Gross margin | 82% | -341% | -143% | 92% | 62% | 62% | 60% | 65% | 97% | n/a |
| R&D | 11.8 | 13.8 | 20.2 | 22.1 | 20.8 | 17.6 | 20.5 | 8.7 | 9.1 | 9.1 |
| Operating income | -5.6 | -23.4 | -30.0 | -4.4 | -28.4 | -24.0 | -26.2 | -12.5 | -15.7 | -13.9 |
| Operating margin | -36% | -3094% | -2002% | -17% | -20006% | -10698% | -16506% | -36650% | -3729% | n/a |
| Pre-tax income | -2.1 | -19.5 | -35.5 | 12.6 | -28.5 | -27.3 | -21.0 | -11.8 | -15.0 | -12.3 |
| Tax rate | n/a | n/a | n/a | 3% | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | -2.3 | -19.8 | -35.5 | 12.3 | -28.5 | -27.4 | -21.0 | -11.8 | -15.0 | -12.3 |
| Net margin | -15% | -2613% | -2373% | 49% | -20092% | -12212% | -13181% | -34618% | -3544% | n/a |
| Diluted EPS | -$0.02 | -$0.14 | -$0.25 | n/a | -$0.20 | -$0.19 | -$0.15 | n/a | -$0.11 | -$0.09 |
| Operating cash flow | -9.1 | -5.4 | -25.6 | -27.5 | -12.3 | -21.8 | -10.9 | -17.3 | -15.6 | 1.5 |
| Capital expenditure | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Free cash flow | -9.1 | -5.5 | -25.7 | -27.5 | -12.3 | -21.8 | -10.9 | -17.3 | -15.6 | 1.5 |
| Shares outstanding | 142m | 142m | 142m | 142m | 142m | 142m | 142m | 142m | 142m | 142m |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A blank figure marked on a quarter is one the filings do not give on their own: the quarters as filed do not add to the year the company filed, or the year and its quarters stand on different share counts. Each quarter's page says which. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.10-Q for the period ended 30 September 2024, filed 6 November 2025: the filing.